Establishment of CD271-targeting therapy

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K18788
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56050:Otorhinolaryngology-related
• Research Institution: Miyagi Prefectural Hospital Organization Miyagi Cancer Center
• Principal Investigator: Fujii Keitaro 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん幹細胞研究部, 共同研究員 (30839379)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: 下咽頭がん

Outline of Final Research Achievements

We have shown that CD271 (nerve growth factor receptor) is essential for tumorigenesis in hypopharyngeal carcinoma, and that CD271-positive cancer cells form a heterogeneous tumor tissue produce both CD271-negative and positive cancer cells. Therefore, if the function of CD271 can be inhibited, it may be possible to reduce the size of the entire tumor. Our studies revealed: 1. therapeutic antibodies targeting CD271-positive cells caused a reduction of overall tumor volume; 2. molecular X is required for CD271 signaling

Free Research Field

頭頸部外科

Academic Significance and Societal Importance of the Research Achievements

私たちはCD271陽性細胞を狙うことで、癌組織全体の治療が可能であることを示した。今後さらに検討を続けることで、臨床応用を狙っていく。